KLF2 and neoplasm: We show that 4-1BB antibody targeted delivery of a KLF2 siRNA to vaccine activated CD8+ T cells in tumor bearing mice leads to increased intratumoral content of Trm cells (Fig. 3) and enhances vaccine mediated inhibition of tumor growth (Fig. 4).